NASDAQ:ENSC Ensysce Biosciences Q3 2026 Earnings Date & Estimates $0.35 -0.02 (-4.29%) As of 02:17 PM Eastern This is a fair market value price provided by Massive. Learn more. Ensysce Biosciences is estimated to report Q3 2026 earnings on Friday, November 13, 2026. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 13, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Ensysce Biosciences in Q3 2026Ensysce Biosciences is expected to post earnings of -$0.12 per share on revenue of $1.20 million. In the same quarter a year earlier Ensysce Biosciences reported -$1.29 per share on revenue of $493.10 thousand. Ensysce Biosciences last reported on August 13, 2026, posting -$0.20 per share and matching the -$0.20 consensus estimate. Ensysce Biosciences has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.12Expected Revenue$1.20 millionPrior-Year EPS-$1.29Prior-Year Revenue$493.10 thousandExpected Revenue Growth+143.4%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.20 (Met Expectations)Last Quarter Revenue$1.16 millionEPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Ensysce Biosciences Q3 2026 Earnings FAQ When does Ensysce Biosciences report Q3 2026 earnings? Ensysce Biosciences (NASDAQ:ENSC) is estimated to report Q3 2026 earnings on Friday, November 13, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Ensysce Biosciences' Q3 2026 earnings call? Ensysce Biosciences' Q3 2026 earnings conference call is scheduled for Friday, November 20, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Ensysce Biosciences? Analysts expect Ensysce Biosciences to post earnings of -$0.12 per share for Q3 2026. How much revenue is Ensysce Biosciences expected to report? The consensus revenue estimate for Ensysce Biosciences is $1.20 million for Q3 2026. Ensysce Biosciences Earnings HeadlinesEnsysce Biosciences (ENSC) Set to Release Quarterly Earnings on FridayNovember 6, 2026 | americanbankingnews.comHead-To-Head Contrast: Merck KGaA (OTCMKTS:MKKGY) and Ensysce Biosciences (NASDAQ:ENSC)October 30, 2026 | americanbankingnews.comExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December. The agenda at the upcoming G20 Summit in Miami has shifted, and new research points to a major monetary announcement from President Trump. A new documentary breaks down what this shift could mean for savings, investments, and the assets tied to it.November 10 at 1:00 AM | Porter & Company (Ad)Ensysce Biosciences average analyst price target cut by 37.88% to $5.23October 22, 2026 | msn.comCantor Fitzgerald initiates coverage of Ensysce Biosciences at overweightOctober 20, 2026 | msn.comEnsysce Biosciences Corporate Event Calendar | NASDAQ:ENSCSeptember 9, 2026 | benzinga.comSee More Ensysce Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ensysce Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ensysce Biosciences and other key companies, straight to your email. Email Address About Ensysce BiosciencesEnsysce Biosciences (NASDAQ:ENSC) is a clinical-stage biotechnology company focused on developing prescription medicines designed to address opioid abuse, misuse and overdose. The company’s technology is intended to preserve the therapeutic benefits of opioid pain medicines while incorporating mechanisms that may reduce the risks associated with tampering or excessive dosing. Ensysce’s lead product candidate, PF614, is an investigational extended-release oxycodone prodrug designed to be activated in the gastrointestinal tract. The company is also developing PF614-MPAR, a product candidate that combines PF614 with its multi-payload abuse-resistance technology and is intended to provide additional protection against opioid misuse and overdose. These products remain investigational and are not approved for commercial use. Based in the United States, Ensysce conducts its development activities through clinical and preclinical programs targeting pain management and opioid safety. The company’s pipeline and platform are focused primarily on the U.S. prescription-medicine market, with potential applications in other markets subject to regulatory review and approval.View Ensysce Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
